Decentralized digital therapeutic trial. Pear Therapeutics has enrolled the first participant in the DREAM study, an open-label trial of its Somryst prescription digital therapeutic for chronic insomnia.
Conducted as a decentralized trial, the effort will recruit U.S. adults aged 22 to 75 years who have an Insomnia Severity Index score of 8 or higher, as well as at least three months of insomnia...
